GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) » Definitions » Cyclically Adjusted FCF per Share

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Cyclically Adjusted FCF per Share : HK$-0.02 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Shenzhen Hepalink Pharmaceutical Group Co's adjusted free cash flow per share for the three months ended in Mar. 2024 was HK$0.607. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is HK$-0.02 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-10), Shenzhen Hepalink Pharmaceutical Group Co's current stock price is HK$3.34. Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was HK$-0.02. Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Shenzhen Hepalink Pharmaceutical Group Co was 240.00. The lowest was 55.87. And the median was 92.83.


Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted FCF per Share Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.09 - -0.04 -0.03

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.05 -0.05 -0.03 -0.02

Competitive Comparison of Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF falls into.



Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Shenzhen Hepalink Pharmaceutical Group Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.607/115.2271*115.2271
=0.607

Current CPI (Mar. 2024) = 115.2271.

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.025 98.200 0.029
201409 0.466 98.900 0.543
201412 0.142 99.000 0.165
201503 0.208 99.900 0.240
201506 0.137 99.500 0.159
201509 0.275 100.500 0.315
201512 0.088 100.600 0.101
201603 0.002 102.200 0.002
201606 -0.015 101.400 -0.017
201609 0.097 102.400 0.109
201612 -0.110 102.600 -0.124
201703 -0.183 103.200 -0.204
201706 -0.244 103.100 -0.273
201709 -0.497 104.100 -0.550
201712 -0.154 104.500 -0.170
201803 -0.207 105.300 -0.227
201806 0.146 104.900 0.160
201809 0.197 106.600 0.213
201812 -0.051 106.500 -0.055
201903 -0.226 107.700 -0.242
201906 -0.093 107.700 -0.099
201909 -0.074 109.800 -0.078
201912 -0.146 111.200 -0.151
202003 -0.253 112.300 -0.260
202006 -0.062 110.400 -0.065
202009 0.051 111.700 0.053
202012 0.092 111.500 0.095
202103 0.304 112.662 0.311
202106 -0.161 111.769 -0.166
202109 -0.164 112.215 -0.168
202112 -0.149 113.108 -0.152
202203 -0.031 114.335 -0.031
202206 -0.245 114.558 -0.246
202209 -0.410 115.339 -0.410
202212 -0.074 115.116 -0.074
202303 -0.210 115.116 -0.210
202306 -0.305 114.558 -0.307
202309 0.124 115.339 0.124
202312 0.344 114.781 0.345
202403 0.607 115.227 0.607

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Shenzhen Hepalink Pharmaceutical Group Co  (HKSE:09989) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Shenzhen Hepalink Pharmaceutical Group Co was 240.00. The lowest was 55.87. And the median was 92.83.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Business Description

Traded in Other Exchanges
Address
No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.
Executives
Orbimed Capital Llc 2102 Investment manager
Morgan Stanley & Co. International Plc 2105 Underwriter
Morgan Stanley International Holdings Inc. 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Avict Global Holdings Limited 2101 Beneficial owner
Worldwide Healthcare Trust Plc 2101 Beneficial owner

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Headlines

No Headlines